Sandro Porceddu: Even low dose cisplatin has an impact on sensorineural hearing loss

Sandro Porceddu, Director of the Department of Radiation Oncology at Peter MacCallum Cancer Centre, shared a post on LinkedIn:

“In another stellar presentation, ANZHNCS ASM Laurelie Wishart presented our findings of hearing outcomes in the randomised TROG 12.01 low risk HPV oropharyngeal cancer study confirming that even low dose cisplatin has an impact on sensorineural hearing loss (albeit substantially less than historical data with high dose cisplatin).

Even patients receiving low dose cisplatin should be evaluated and counseled regarding hearing loss.”

Source: Sandro Porceddu/LinkedIn